帕利哌酮与利培酮治疗精神分裂症的安全性对照研究

目的 比较帕利哌酮与利培酮治疗精神分裂症的安全性.方法 将符合CCMD-3精神分裂症诊断标准的70例患者随机分为两组,分别给予帕利哌酮和利培酮治疗,共12周.采用阳性和阴性症状量表（PANSS）和锥体外系副作用量表（TESS）评分.结果 治疗12周后帕利哌酮组和利培酮组的显效率分别为67.7％、63.6％,差异无统计学意义（P＞0.05）.两组治疗后各时点PANSS总分及各因子分比较差异也无统计学意义（P＞0.05）.帕利哌酮组的主要副作用为焦虑、静坐不能、肌张力增高,与利培酮组相当,差异无统计学意义（P＞0.05）;而体重增加、月经紊乱、血糖、血脂增高的发生率显著低于利培酮组（P＜0.05）.结论 帕利哌酮、利培酮治疗精神分裂症效果相当,主要副作用表现为锥外系副作用,出现代谢综合征少,对肝功能几乎无影响,为疗效好、安全性高的抗精神病药,但要注意其锥体外系副作用.

Security control study of Paliperidone and Risperidone in the treatment of schizophrenia

Objective To compare security of Paliperidone and Risperidone in the treatment of schizophrenia.Methods 70 patients who met criteria for schizophrenia in the Chinese classification and diagnostic criteria of mental disorders third edition （CCMD-3） were randomly assigned to 2 groups,which were given Paliperidone （n =35） or Risperidone （n =35） treatment for 12 weeks.The efficacy and safety were eassessed with the positive and negative symptoms scale （PANSS） and the treatment emergent symptom scale （TESS）.Results After 12 weeks treatment,the response rates of Paliperidone was 67.7％,and Risperidone was 63.6％,without significant difference.Meanwhile,the scores of PANSS had no significant difference at different points in time after treatment （P ＞ 0.05）.The main incidence of adverse events of Paliperidone were anxiety,akathisia and increased muscle tension,which had no significant differences from Risperidone group （P ＞ 0.05）.The increased incidences of weight,menstrual disorders,blood sugar,blood fat in the Paliperidone group were significantly lower than the Risperidone group （P ＜ 0.05）.Conclusion Paliperidone and Risperidone have considerable effect in the treatment of schizophrenia.Their major side reaction is extra pyramidal side effect,and metabolic syndrome appears seldom,and almost no effect acts on liver function.They are antipsychotic drugs with good curative effect and high safety,simultaneously doctors should pay attention to their extra pyramidal side effects.